UPDATE: Exact Sciences Q4 Revenues Balloon on Cologuard Sales | GenomeWeb

This article has been updated to include information from Exact's analyst conference call.

NEW YORK (GenomeWeb) – Exact Sciences reported today that its fourth quarter revenues grew nearly 10-fold year over year thanks to completing 38,000 Cologuard colorectal cancer screening tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.